Your dedication to saving women’s lives
is what drives us to offer


Aptima® HPV
mRNA Assay

One of the most significant innovations in
cervical cancer screening in over a decade.

Know the facts about the Aptima HPV Test

  • Offers excellent sensitivity
  • Offers increased specificity2
  • FDA-approved for use with ThinPrep®
  • Aligns with cervical cancer screening guidelines
  • Requires only 1 mL of specimen2
  • Same price and coverage as DNA-based HPV tests
  • No increased costs to you or your patients
  • Only assay to genotype 16, 18/45 to identify almost
    all HPV types associated with cervical adenocarcinoma
The pivotal study, known as the CLEAR (Clinical Evaluation of Aptima HPV RNA) Trial was a prospective, multicenter clinical study that analyzed more than 11,000 women undergoing routine Pap testing at 18 US clinics. The CLEAR Trial comprised two arms:
  1. The ASCUS Study population included 939 women <21 years with ASCUS cytology results
  2. The NILM (Adjunct) Study population included 10,871 women <30 years with normal cytology results

With the Aptima HPV Test—FDA-approved for use in ThinPrep®
—you can focus on more clinically relevant results.

mRNA and Cervical Disease

For more information, contact your sales representative
or call 1-866-MYQUEST (1-866-697-8378).